Stockwinners Market Radar for January 10, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:31 EST Chi-Med, Inmagene partner to develop candidates to treat immunological diseases - Hutchison China MediTech and Inmagene Biopharmaceuticals announced a strategic partnership to further develop four novel preclinical drug candidates discovered by Chi-Med for the potential treatment of multiple immunological diseases. Funded by Inmagene, the companies will work together to move the drug candidates towards investigational new drug submission. If successful, Inmagene will then move the drug candidates through global clinical development. Under the terms of the agreement, Chi-Med grants Inmagene exclusive options to four drug candidates solely for the treatment of immunological diseases. Should Inmagene exercise the option, it will have the right to further develop, manufacture and commercialize that specific drug candidate worldwide, with Chi-Med retaining first right to co-commercialization in mainland China. For each of the drug candidates, Chi-Med will be entitled to development milestones of up to $95M and up to $135M in commercial milestones, as well as up to double-digit royalties upon commercialization.

20:21 EST BioMarin announces topline results from ongoing global Phase 3 GENEr8-1 study - BioMarin Pharmaceutical has announced positive topline results from its ongoing global Phase 3 GENEr8-1 study of valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A. This is the largest global Phase 3 study to date for any gene therapy in any indication, with 134 participants. All participants in the study received a single dose of valoctocogene roxaparvovec and completed a year or more of follow-up. Data from the GENEr8-1 Phase 3 study with a mean follow-up of 71.6 weeks showed that in the pre-specified primary analysis for Annualized Bleeding Rate a single dose of valoctocogene roxaparvovec significantly reduced ABR by 84% from a prospectively collected 4.8 at baseline to 0.8 bleeding episodes per year, among a pre-specified group of prior participants in a non-interventional baseline observational study. 80% of participants were bleed-free starting at week five after treatment. Valoctocogene roxaparvovec also significantly reduced the mean annualized Factor VIII in the rollover population by 99% from 135.9 to 2.0 infusions per year. At the end of the first year post-infusion with valoctocogene roxaparvovec, participants in the modified intent-to-treat population had a mean endogenous Factor VIII expression level of 42.9 IU/dL, as measured by the chromogenic substrate assay, supporting the marked clinical benefits observed with abrogation of bleeding episodes and Factor VIII infusion rate. Factor VIII expression declined at a slower rate compared to the Phase 1/2 study, and remained in a range to provide hemostatic efficacy. In a subset of the mITT population that had been dosed at least two years prior to the data cut date, Factor VIII expression declined from a mean of 42.2 IU/dL at the end of year one to a mean of 24.4 IU/dL at the end of year two with continued hemostatic efficacy demonstrated by a mean ABR of 0.9 bleeding episodes per year. Overall, in the Phase 3 study, valoctocogene roxaparvovec has been well tolerated by the 134 participants who received a single 6e13 vg/kg dose. No participants developed inhibitors to Factor VIII, or thromboembolic events. One participant was lost to follow-up. Infusion-related reactions were effectively mitigated by managing infusion rates. Alanine aminotransferase elevation, a laboratory test of liver function, remained the most common adverse event. Common, steroid-related side effects can occur with temporary use of corticosteroid to manage ALT elevation. These side effects have generally been grade 1/2 in intensity, manageable and reversible. Isolated grade 3 steroid-related sides effects were observed with longer-term higher dose corticosteroid administration. Corticosteroid-related grade 3 SAEs emerged as a safety issue with extended use of corticosteroids which were reversible with only one event of weight gain ongoing. Overall, in the Phase 1/2 study, the safety profile of valoctocogene roxaparvovec remains consistent with previously reported data with no delayed-onset, treatment-related events. No participants developed inhibitors to Factor VIII, and no participants withdrew from the study. No participants have developed thrombotic events. The most common adverse events associated with valoctocogene roxaparvovec occurred early and included transient infusion-associated reactions and transient, asymptomatic, and mild to moderate rise in the levels of certain proteins and enzymes measured in liver function tests with no long-lasting clinical sequelae.

17:29 EST Cognizant to acquire Servian - Cognizant announced it has entered into an agreement to acquire Servian, a Sydney, Australia-based, privately-held enterprise transformation consultancy specializing in data analytics, artificial intelligence, digital services, experience design, and cloud. Servian is Cognizant's 10th digital-focused acquisition announced since January 2020, highlighting Cognizant's strategy to accelerate capabilities and growth in priority areas of data and artificial intelligence, digital engineering, cloud, and Internet of Things across the globe. The transaction is expected to close in the first quarter of 2021, subject to regulatory clearance and other closing conditions. Financial details were not disclosed.

15:28 EST StoneX, City Index announce four-year sponsorship deal with Saracens Rugby - StoneX announced that its London-based subsidiary, StoneX Financial, has entered into a four-year partnership with rugby club Saracens. Beginning in January 2021, StoneX will become Saracens' main club sponsor and its home ground in London will be named StoneX Stadium. Award-winning broker and leading trading platform, City Index, the London-based subsidiary of Gain Capital which was acquired by StoneX in July 2020, will be featured as lead partner on both the men's and women's kits.

15:20 EST Nio partners with Nvidia to develop new generation of automated driving EV - Nio Inc. (NIO) and Nvidia (NVDA) announced that the automaker has selected the NVIDIA DRIVE Orin system-on-a-chip for its new generation of electric vehicles, which will offer advanced automated driving capabilities. At Nio Day, the company's annual customer event, the EV maker revealed its NVIDIA DRIVE Orin-powered supercomputer, dubbed Adam, which will first appear in the ET7 sedan that will ship in China starting in 2022. As the first of NIO's EVs to feature Orin, the flagship ET7 is a high-performance vehicle that accelerates from zero to 100km in only 3.9 seconds. It also features a new 150kw battery for extended mileage range.